Autoimmune Diseases  >>  Tysabri (natalizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tysabri (natalizumab) / Biogen, Royalty
NCT00027300: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Checkmark AAN 2015: Multiple sclerosis (AFFIRM)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (AFFIRM)
Checkmark AFFIRM
Nov 2014 - Nov 2014: AFFIRM
Checkmark ACTRIMS-ECTRIMS 2014: MS (AFFIRM)
More
Completed
3
900
US, Canada, Europe
Natalizumab, Tysabri, Placebo
Biogen, Elan Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
11/04
01/05
NCT00030966: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Completed
3
1200
US, Europe, RoW
Natalizumab, Tysabri, Placebo
Biogen, Elan Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
04/05
12/05
NCT00306592: Natalizumab Re-Initiation of Dosing

Completed
3
404
US, Canada
BG00002 (natalizumab), Tysabri
Biogen, Elan Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
12/07
02/08
SURPASS, NCT01058005 / 2009-015556-15: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Checkmark Interim data
Oct 2010 - Oct 2010: Interim data
Terminated
3
84
US, Canada, Europe, RoW
BG00002 (natalizumab), Tysabri, interferon beta-1a, Rebif, glatiramer acetate, Copaxone
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
04/12
04/12
TOFIINGO, NCT01499667 / 2011-001442-15: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Checkmark TOFINGO
Oct 2013 - Oct 2013: TOFINGO
Checkmark ECTRIMS 2013: Multiple sclerosis (TOFIINGO)
Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis (TOFIINGO)
Terminated
3
142
Europe, RoW
Fingolimod, Placebo
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
11/12
11/12
STRATA, NCT00297232 / 2005-004061-41: Natalizumab (Tysabri) Re-Initiation of Dosing

Checkmark AAN 2015: Multiple sclerosis (STRATA)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (STRATA)
Checkmark STRATA
Jun 2014 - Jun 2014: STRATA
Checkmark EFNS-ENS 2014: MS (STRATA)
More
Terminated
3
1094
Canada, Europe, RoW
Natalizumab, Tysabri (BG00002)
Biogen
Relapsing-Remitting Multiple Sclerosis
04/14
04/14
ASCEND, NCT01416181 / 2010-021978-11: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

Checkmark ASCEND-ISPOR-Eu 2015
Nov 2015 - Nov 2015: ASCEND-ISPOR-Eu 2015
Checkmark ASCEND
Oct 2015 - Oct 2015: ASCEND
Checkmark CMSC 2015
More
Terminated
3
889
US, Canada, Europe, RoW
natalizumab, Tysabri, BG00002, Placebo
Biogen
Secondary Progressive Multiple Sclerosis
07/15
04/16

Download Options